Among these six trials completed, one randomized multicenter phase II research trial evaluating two administration doses of TG4010 (MVA-MUC1-IL2) in patients with terminated PCa and one Ad-sig-hMUC-1/ecdCD40L vector vaccine for metastatic or recurrent PCa trial status unknown. The gene discussed is MUC1; the disease is posterior cortical atrophy.